Evidence map›Paper›PMID 42701446›Full record

ArticleMaterials today. Bio2026

Engineered bacteria reverses tumor cuproptosis resistance via cancer-associated fibroblast reprogramming for enhanced immunotherapy.

Yuhao Chen, Xiaorui Geng, Ning Su, Phei Er Saw, Yun Li, Bin Liu, Yingjia Li, Zhen Yuan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuhao ChenDepartment of Public Health and Medicinal Administration, Faculty of Medicine, University of Macau, China.
Xiaorui GengDepartment of Public Health and Medicinal Administration, Faculty of Medicine, University of Macau, China.
Ning SuDepartment of Public Health and Medicinal Administration, Faculty of Medicine, University of Macau, China.
Phei Er SawMedical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Yun LiGuangdong Yunzhao Medical Technology Co., LTD, Guangzhou, China.
Bin LiuDepartment of Emergency, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China.
Yingjia LiDepartment of Medicine Ultrasonics, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Zhen YuanDepartment of Public Health and Medicinal Administration, Faculty of Medicine, University of Macau, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cuproptosis, a novel modality of mitochondrial copper-induced cell death, holds great therapeutic potential against cancer. However, its efficacy is limited by cancer-associated fibroblasts (CAFs), which confer the cuproptosis resistance in tumor by upregulating the copper exporter ATP7A. In this study, we developed an engineered bacteria system, PCuS-MG, for synergistic cuproptosis and immunotherapy via CAFs reprogramming. PCuS-MG consists of

Indexed as

BacteriaCancer-associated fibroblasts (CAFs)CuproptosisImmunotherapyTumor microenvironment

Identifiers

PMID42701446
PMCPMC13545382

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.